

Broomfield et al Title Page

Long Term Quality of Life Following Vestibular Schwannoma Excision via the Translabyrinthine Approach

Short Running Head: Quality of Life after Vestibular Schwannoma surgery

Stephen J Broomfield MBChB, FRCS(ORL-HNS)

University Hospitals Bristol NHS Foundation Trust

Ashish K Mandavia MBChB, BSc

University of Bristol

Jack S Nicholson MBChB, BSc, MSc

University of Bristol

Osama Mahmoud PhD

School of Social and Community Medicine, University of Bristol

Department of Applied Statistics, Helwan University, Cairo

Andrew T King

Department of Neurosurgery, Salford Royal NHS Foundation Trust

Manchester Academic Health Science Centre, Manchester, UK

University of Manchester

Scott A Rutherford MBChB FRCSEd(Neuro.Surg)

Department of Neurosurgery, Salford Royal NHS Foundation Trust

Manchester Academic Health Science Centre, Manchester, UK

Richard T Ramsden MBE, FRCSEd(ad hominem), FRCS Eng

Central Manchester University Hospitals NHS Foundation Trust

Salford Royal NHS Foundation Trust

Corresponding author:

Mr Stephen Broomfield

Department of Otolaryngology Head and Neck Surgery
University Hospitals Bristol NHS Foundation Trust
St Michael's Hospital
Southwell Street
Bristol BS2 8EG

Tel: 0117 342 1839

Email: Stephen.Broomfield@UH Bristol.nhs.uk

Acknowledgements:

The authors would like to thank Mrs Natalie Whalley in the department of Otolaryngology Head and Neck Surgery at the Manchester Royal Infirmary for her help with the administration of this study.

Conflicts of Interest and Sources of Funding:

None declared

1 Introduction

2 Vestibular schwannomas, commonly known as acoustic neuromas, are a benign tumour of the
3 eighth cranial nerve and the commonest lesion of the cerebellopontine angle. With improved access
4 to magnetic resonance imaging (MRI), vestibular schwannomas are increasingly diagnosed at an
5 early stage. Whilst surgery remains the mainstay of treatment for large tumours, there are several
6 management options for small and medium-sized tumours. These include conservative
7 management (so-called 'wait and rescan'), radiation treatment (gamma knife radiosurgery or
8 stereotactic radiotherapy), or microsurgical excision (with a variety of surgical approaches). The
9 possibility of hearing preservation, new radiation dosing regimens, subtotal surgical excision and
10 combination therapies have further complicated decision making in this already complex field. For
11 this reason, there has been increasing interest in quality of life (QOL) outcomes in patients with
12 vestibular schwannomas, though it is not yet clear how QOL outcomes can be used in the decision-
13 making process.¹⁻³ As some of the impact on QOL undoubtedly comes from the diagnosis itself,
14 rather than the treatment, adequate psychosocial support for vestibular schwannoma patients is
15 critical.⁴ For patients undergoing treatment, counselling must give some realistic expectation of
16 long-term outcome, whichever treatment modality is chosen. The aim of this study was to examine
17 a large series of patients undergoing translabyrinthine surgery under a single surgeon and report
18 long term post-operative QOL results as well as more disease-specific outcomes.

19 Materials and Methods

20 Five hundred consecutive patients who had translabyrinthine surgery for vestibular schwannoma
21 under the care of the senior author (RTR) either as sole surgeon or working as part of the joint
22 Neuro-otology /Skull Base team at Manchester Royal Infirmary and Salford Royal Hospital were
23 identified. The cases were taken from a larger database of approximately 2000 vestibular
24 schwannomas managed between 1978 and 2009, including over 1200 operated tumours. The series
25 under study had a minimum follow up of 5 years. Patients with neurofibromatosis type 2 and those
26 who underwent alternative surgical approaches (middle fossa, retrosigmoid, suboccipital) were
27 excluded. Subjects were sent two surveys by post; the 36 item Short Form Health Survey (SF-36,
28 Medical Outcomes Trust), and an additional generic post-operative quality of life (QOL) survey
29 (hereon referred to as QOL-2) devised by the authors to assess the more subjective elements of
30 outcome from surgery (appendix 1). Items assessed with the QOL-2 survey included pre- and post-
31 operative symptoms (self-graded as 'mild', 'moderate' or 'severe'), and subjective assessment using
32 5-point Likert scales to measure overall quality of life, overall health and mood as well as post-
33 operative ability to work, drive and perform sports/hobbies. Demographic data collected from the

34 database included patient gender and age, year of surgery and tumour size (measured as the
35 maximum intracranial transverse diameter of the tumour in cm on the pre-operative MRI scan).
36 Purely intra-canalicular tumours were treated as a separate category, with other tumours
37 categorised into groups according to the tumour size (see results).

38 Scoring of the SF-36 surveys was performed according to the manual as previously described.⁵
39 Scores generated ranged from 0 (worst possible QOL) to 100 (best possible QOL). Continuous
40 variables were described using means with standard deviations (SD) when their distribution was
41 found to be normal, and medians with interquartile ranges (IQR) when their distribution was
42 skewed. Categorical variables were described using frequency counts and percentages. Statistical
43 analysis was performed using IBM SPSS for Windows version 23. Statistical tests were performed 2-
44 sided and the p values obtained were presented to quantify evidence against the null hypothesis.
45 Ethical approval was granted prior to the commencement of this study (NHS National Research
46 Ethics Service Ref 04/Q1402/56).

47 Results

48 *Overall Demographics*

49 In total, 334 patients returned the SF-36 survey and 369 the QOL-2 survey, giving response rates of
50 67% and 74%, respectively. The mean age of respondents at time of surgery was 51.9 (SD 11.3)
51 years for the SF-36 group and 52.5 (SD 11.2) years for the QOL-2 group. There was a female
52 preponderance of 57% in both groups. The median tumour size for all responders was 1.5cm (IQR 1-
53 2.5 cm). The median duration of follow-up was 8 years (mean 8.23 years, IQR 7-10 years).

54 There was no statistical evidence for differences in gender, tumour size or length of follow-up
55 between responders and non-responders for either survey, nor in age for the SF-36 group. For age
56 in the QOL-2 group, responders were found to be 3.8 (CI 1.5 – 6.2) years older than non-responders.
57 This difference was found to be statistically significant ($p < 0.05$) but not felt to be clinically important.

58 *Short-Form 36 Survey Results*

59 Table 1 shows the results of the short-form 36 (SF-36) survey for each of the 8 domains: Overall
60 physical functioning (PF), role limitations due to physical health (RP), bodily pain (BP), general health
61 (GH), vitality (VT), social functioning (SF), role limitations due to emotional health (RE), and general
62 mental health (MH). Component scores for total physical (TPCS) and mental health (TMCS) are also
63 shown. Values for an age-matched UK population are shown for comparison.⁶ Figure 1 presents a
64 graphical comparison between means of the SF-36 scores from our study and an age-matched UK

65 population. T-tests were performed to examine the observed difference between means for each
66 domain; the resulting p values are reported in figure 1. There was strong evidence that scores from
67 this study differ from the UK normative values for all domains except for the 'Role Emotional', where
68 there was no statistical evidence for the difference ($p=0.1$).

69 Tumours were categorised into groups according to tumour size (Table 2). Linear regression analysis
70 was performed to look for an association between tumour size and the SF-36 total physical (TPCS)
71 and mental (TMCS) component score domains, adjusting for age as a potential confounding factor
72 (Table 3). A group of the smallest tumours, consisting of intra-canalicular and less than 1cm tumours
73 ($n=55$), was used as the reference category. For the TMCS domain, a patient with tumour size of
74 4cm or over was likely to have 3.4 less score than a patient (of the same age) with a tumour of less
75 than 1cm. There was some evidence supporting this effect ($p = 0.037$). There was little evidence for
76 the effect of smaller tumour sizes on the TMCS score and no evidence for tumour size effect on the
77 TPCS domain.

78 Table 4 shows the correlation coefficients between age and the SF-36 domains. Pearson correlation
79 tests showed that statistically significant correlation was observed in several of the SF-36 domains;
80 PF, RP, BP, VT, MH, TPCS and TMCS. In some domains, mainly the physical subscales, this was a
81 negative correlation whereas in others, mainly the mental subscales, the correlation was positive;
82 the correlation coefficients for the TPCS and TMCS were -0.26 and +0.26, respectively.

83 Effect of time elapsed since surgery on the SF-36 domain scores was investigated using linear
84 regression models, taking into account both age and tumour size. Improvement in component
85 scores for total mental health was associated with increased time since surgery ($p=0.005$). A patient
86 was found to have 0.3 higher score of total mental health than a patient (from the same age and
87 tumour size category) who underwent surgery one year later. There was no relationship between
88 the physical subscales or the total physical component score and time since surgery.

89 *Results of the generic post-operative survey (QOL-2)*

90 When asked about the effect of the operation, a significant proportion of patients reported an
91 improvement ('a lot' or 'a little' better) in their overall quality of life (24%) and overall health (20.4%)
92 (Table 5).

93 Statistical analysis (Spearman's rank correlation test) showed a positive correlation between the SF-
94 36 total physical component score and patients' self-assessment of overall quality of life (correlation
95 0.26, $p<0.01$) and overall health (correlation 0.5, $p<0.01$). This correlation was not seen between

96 these measures and the total mental component score (quality of life; correlation 0.01, $p=0.91$ and
97 health; correlation -0.02 , $p=0.77$).

98 Of the 318 respondents in employment at the time of the survey, 195 (61.3%) continued in the same
99 employment following their surgery. A further 22 (6.9%) chose to change their job following
100 surgery, and 48 (15.1%) chose to retire. Fifteen (4.7%) and 38 (11.9%) respondents, respectively, felt
101 forced to change job or to retire for medical reasons as a direct result of their operation. Of 300
102 respondents who were car drivers prior to surgery, 253 (84%) continued driving normally after a
103 break (duration not specified in this study). A further 29 (10%) continued driving but with limited
104 ability; 11 (4%) chose and 7 (2%) respondents felt forced to give up driving altogether.

105 When asked about the effect of the operation on ability to continue with sports or hobbies, 153 of
106 351 respondents (44%) continued as before, after a break (unspecified duration). A further 111
107 (32%) continued with ability limited a little and 39 (11%) with ability limited a lot. Forty-eight (14%)
108 respondents chose to (7%) or felt forced to (7%) give up their previous sports or hobbies.

109 Seventy of 361 respondents (19%) reported feeling more positive following surgery. A further 133
110 (37%) had no change in their mood; 92(25%) and 37 (10%) reported feeling occasionally or
111 frequently anxious or low in mood, respectively. Twenty-nine (8%) had felt depressed or required
112 treatment for low mood/ depression. The response to this question correlated strongly with the SF-
113 36 mental health subscale (correlation score $=0.2$) and total mental component score (correlation
114 score $= 0.23$). Spearman's rank correlation tests showed that these results were statistically
115 significant ($P<0.01$) in both cases.

116 Based on the senior author's previous anecdotal experience of post-operative reports from
117 vestibular schwannoma patients, respondents were asked to report their experience of unusual or
118 vivid dreams or nightmares. Of the 364 respondents, 55 (15%) could not recall and 181 (50%) had
119 not experienced vivid dreams or nightmares. These were experienced, however, by 59 (16%)
120 respondents for a few days, by 36 (10%) for a few weeks and by 33 (9%) for months or years after
121 surgery.

122 When asked to report how their actual experience of their operation and recovery compared with
123 their expectation, 160 of 361 (44%) respondents reported a better experience than expected, 58
124 (16%) the same as expected and 143 (40%) worse than expected.

125 Respondents were asked to grade their pre- and post-operative symptoms according to how much
126 they affected daily life (washing, dressing, going out, work, housework etc.) both before and after

127 surgery. These results are summarised in table 6 as a cross-tabulation of pre- and post-operative
128 results to show how the number of patients experiencing each symptom changed following surgery.

129 Discussion

130 *Quality of Life*

131 We present the results of a quality of life (QOL) survey of 500 patients who had undergone
132 translabyrinthine excision of vestibular schwannoma, representing one of the largest single-surgeon
133 experiences reported to date. To assess long-term post-operative QOL, the Short-Form 36 (SF-36)
134 tool was selected. The SF-36 has been validated for use in QOL assessment and utilised for many
135 diseases. It has the advantage of being comparable with published general population norms as well
136 as with other studies of vestibular schwannoma surgery (Table 7).^{4,7-19} We supplemented the SF-36
137 with additional disease-specific questions relating to vestibular schwannoma treatment.

138 This study found that all 8 of the domains of the SF-36, as well as the 2 component scores, were
139 reduced following vestibular schwannoma surgery compared to the general population. This has
140 been reported previously.¹⁵ Other studies have found lower SF-36 outcomes in multiple (but not all)
141 domains.^{13,16,17,19,20} Interestingly, as in our study, some authors have found a particularly significant
142 reduction in post-operative social functioning.^{18,21} Cheng et al showed a QOL comparable to the
143 normal population in 7 of 8 SF-36 domains.¹⁰ Conversely, one prospective study of 15 patients
144 undergoing microsurgery reported improved post-operative QOL at six months compared to pre-
145 operatively and in comparison with age- and sex-matched norms.²²

146 Studies of larger tumours (>3cm) have shown a reduction in quality of life when compared to the
147 general population both before and immediately following surgery.^{7,9,14} In this group, an
148 improvement in QOL over time has been demonstrated.^{7,23} Several published studies have found no
149 relationship between tumour size and QOL outcomes.^{8,10,20,24} Others have shown worse QOL
150 outcomes in patients with larger tumours.^{14,15,19} In a multivariate analysis, Carlson *et al.* found that
151 large tumour size predicted the SF-36 mental component score.²⁵ Irving *et al.* found that quality of
152 life, measured with the EORTC, did relate to tumour size when comparing small tumours to all
153 tumours larger than 1.5cm, but found no difference between medium (1.5 to 2.5cm) and larger
154 tumours.²⁶ Interestingly, patients with smaller tumours may experience a particularly noticeable
155 deterioration in QOL even if the absolute reduction in QOL is less than that seen with larger
156 tumours.²⁷ In our study, there was no correlation between the raw SF-36 scores and tumour size.
157 Using linear regression to allow for age difference, however, patients with the largest tumours

158 (>4cm) were found to have a reduced mental component score (but not physical component score)
159 compared to a reference group of those with the smallest tumours (1cm or less).

160 Several previous studies have shown better QOL outcomes in younger patients.^{7,15} Conversely,
161 others have found a trend towards improvement in post-operative QOL in older patients.^{14,24} Others
162 have shown that age had no effect on QOL.^{10,26,27} In our series, there was a negative correlation
163 between age and the physical subscales of the SF-36 (such that advancing age was associated with
164 reduced QOL) but a positive correlation with the mental subscales. Carlson *et al.* also found that
165 advancing age correlated with the physical but not the mental components of the SF-36.²⁵ Brooker
166 *et al.* reported a similar relationship between the SF-12 (short version of the SF-36) and physical
167 components, but no relationship with the mental components.²⁸ Other studies have found no
168 correlation between age and mental components of the SF-36 and a variable relationship with the
169 physical.^{17,19,20,29} This could reflect the fact that older patients might be expected to be more
170 susceptible to physical impairments. Conversely, older patients may be expected to have more
171 realistic expectations of outcomes, more stable careers, better financial reserves and more
172 developed coping strategies, thereby potentially improving their mental component scores.²⁴ We
173 also found that the mental component score correlated with the time elapsed since surgery, after
174 adjusting for age and tumour size, possibly suggesting improved coping strategies and adaptation
175 over time.

176 When a reduction in post-operative QOL is identified, it is of course difficult to quantify how much it
177 relates to the disease process itself, and how much to the treatment. Studies have demonstrated
178 reduced SF-36 scores compared with a matched population following diagnosis, prior to any
179 treatment.^{22,29,30} This suggests that reduced post-operative QOL relates in part to the disease
180 process, explaining why some studies have failed to show a significant difference in QOL between
181 the three treatment modalities of watchful waiting, radiation treatment and surgical treatment.^{4,23}
182 The effect of the disease on QOL may be related to symptoms from the disease, and treatment may
183 rarely be advocated in order to resolve symptoms e.g. intractable vertigo.¹³ The psychological impact
184 of a diagnosis of vestibular schwannoma is well recognised; the impact of anxiety about the
185 diagnosis or disease progression on QOL must be considered when deciding on an individual's
186 treatment.^{4,31}

187 Despite the overall drop in SF-36 QOL scores, this study found that 24% and 20.4% reported a
188 subjective improvement in overall quality of life and overall health, respectively. Subjective
189 improvement in QOL has been reported previously; in one series of 42 vestibular schwannomas, 67%
190 patients evaluated their health status as unchanged and more reported an improvement (21%) than

191 a deterioration (12%) despite a reduction in overall SF-36 scores.¹⁶ Others have postulated that
192 patients having surgery may have a greater sense of definitive treatment than those being
193 observed.²³ Older patients may be anxious about the possibility of requiring future surgery when
194 they may be less fit.³² Browne *et al.* reported that 81% of vestibular schwannoma patients
195 experienced at least one positive benefit following diagnosis and treatment.¹¹ Lifestyle changes
196 made through choice rather than necessity may have a positive impact on QOL. For example, a
197 patient who chooses to retire might notice an improved QOL despite any new post-operative
198 physical or mental problems. In this study, 61.3% continued in the same job, with 22% and 16.6%,
199 respectively, choosing to or feeling forced to change job or retire. Previous studies have reported
200 similar outcomes.^{14,15,17,19,33} We found that patients' subjective change in mood correlated strongly
201 with the SF-36 mental health subscale. Whilst 37% reported no change in mood, a significant
202 proportion (19%) reported feeling more positive. More importantly, 25% felt occasionally, and 10%
203 frequently, anxious or low. Depression was experienced and/or required treatment in 8%. The
204 potential psychological impact of vestibular schwannoma treatment, the importance of appropriate
205 counselling and support and the need for new psychological outcome measures are well
206 recognised.^{11,14,30,33-36} In this study, 60% of respondents described their overall experience of surgery
207 'about the same' or 'better' than expected and 40% 'worse than expected'. This further highlights
208 the need for optimal pre-operative counselling and post-operative support. Previous UK studies
209 have drawn attention to patients' dissatisfaction with community services, with the majority feeling
210 unsupported.^{36,37}

211 *Symptoms*

212 The incidence of post-operative symptoms reported in this study are similar to those reported
213 previously, including in surveys of national Acoustic Neuroma Associations; hearing loss, balance
214 problems, tinnitus, facial weakness, headache and eye problems being the commonest
215 complaints.^{9,11,19,37-39} As hearing loss is a necessity in translabyrinthine cases, it is unsurprising that in
216 our study the effect of hearing loss on daily life was improvement in only 6.6% post-operatively and
217 was most commonly unchanged (54.4%).

218 Factors other than hearing loss are often found to have a greater impact on QOL; hearing
219 preservation may not be associated with an improved QOL outcome.²¹ The exception is the
220 devastating impact on social integration arising from bilateral hearing loss, as reported in our
221 department's prior study of patients with neurofibromatosis type 2.⁴⁰ Nonetheless, several studies
222 have found imbalance and/or headache to have a greater effect on post-operative QOL than hearing
223 loss or facial weakness.^{17,19,25,38} Episodic vertigo is recognised as being particularly detrimental to

224 QOL in both treated and conservatively managed patients.^{13,41-43} Conversely, some patients will
225 continue a nearly normal life despite a severe facial palsy.^{9,44}

226 Facial weakness is unsurprisingly most common in patients with larger tumours, and tends to have a
227 greater impact on QOL in females.⁴⁵ Dry eyes relating to facial weakness, though rarely reported,
228 are not uncommon for those with larger tumours. Rameh & Magnan reported that 36% of post-
229 operative patients were 'mildly bothered' and 21.3% 'very bothered' by dry eyes; similar to our
230 report of 24.2% of patients with a mild effect on daily activities and 33.2% with a moderate to severe
231 effect from eye symptoms.⁹

232 In this study, vivid dreams or nightmares were experienced by 35% of 364 respondents. The senior
233 author (RTR) had noticed patients reporting this occurrence and has previously reported recurrent
234 dream-like, usually frightening, multi-coloured visual and tactile hallucinations in the initial post-
235 operative period in 53% of patients following vestibular schwannoma surgery, compared to 17% of
236 patients undergoing posterior fossa brain surgery.⁴⁶ Although the mechanism of such phenomena is
237 unknown, hypnagogic hallucinations secondary to pontine vascular insufficiency has been
238 hypothesised.⁴⁶ To our knowledge this is the first report of such symptoms affecting sleep for a
239 prolonged period following vestibular schwannoma surgery.

240 The methodological drawbacks in this study include the potential for recall bias when retrospectively
241 assessing patients' views on their surgical treatment. This may be minimised to some extent by the
242 large number of patients who responded to the survey and the demographic similarity between
243 responders and non-responders. Objective assessment of symptoms (e.g. self-assessment of facial
244 nerve function) was not attempted as previous studies have demonstrated a poor correlation with
245 clinical assessment.¹⁹ In this study we used the SF-36 tool as a measure of generic post-operative
246 QOL. The SF-36 is the most commonly used tool for this purpose, allowing comparison between
247 studies, though the differences in patient populations and study design make direct comparisons
248 difficult (Table 7).^{4,7-19} There are certainly drawbacks to using the SF-36 due to its failure to assess
249 many of the specific issues relevant to vestibular schwannoma treatment.² As in other published
250 studies, we allowed for this by including additional, disease-specific questionnaire items. In this
251 study, it was not possible to enquire about the details of some aspects of patients' outcomes e.g.
252 questions concerning 'return to work' or 'sports and hobbies' did not differentiate between active
253 and sedentary activities. Whilst unlikely to alter the conclusions of the study, differences in these
254 areas would be interesting to observe. With the increased interest in QOL outcomes, it is likely that
255 future vestibular schwannoma research will utilise disease-specific tools as well as both pre- and
256 post-operative QOL assessments.^{1,2,25,47}

257 Conclusion

258 In this survey of 500 patients undergoing translabyrinthine surgery for vestibular schwannoma under
259 a single surgeon, post-operative QOL measured with the SF-36 was found to be significantly lower
260 than that of the general UK population. Despite this fact, nearly a quarter of patients reported a
261 subjective improvement in their QOL. This reflects the complicated nature of both quality of life
262 measurement and the multi-faceted effect of the diagnosis and treatment of vestibular schwannoma
263 for an individual patient. Tumour size was found to have an effect only on the mental component
264 score of the SF-36 for tumours larger than 4cm. Increased age at time of surgery was associated
265 with a reduction in the physical component of QOL and an improved mental component, the latter
266 also improving with time following surgery. Our report of pre- and post-operative symptoms was in
267 line with previously published studies, and highlights the importance of assessing post-operative
268 headache and imbalance as well as hearing loss and facial function.

269 Quality of life outcomes are an important measure for patients undergoing treatment of vestibular
270 schwannoma, the management of which is becoming increasingly complicated as the number of
271 available treatment protocols grows. Generic and disease-specific tools should be a routine part of
272 the assessment of vestibular schwannoma patients. Patients requiring surgery can then be
273 accurately counselled about the likely outcomes, balanced against the potentially serious
274 consequences of their vestibular schwannoma if untreated.

References

1. Gouveris HT, Mann WJ. Quality of life in sporadic vestibular schwannoma: a review. *ORL J Otorhinolaryngol Relat Spec* 2010;72:69-74.
2. Gauden A, Weir P, Hawthorne G, Kaye A. Systematic review of quality of life in the management of vestibular schwannoma. *J Clin Neurosci* 2011;18:1573-1584.
3. Symonds T, Berzon R, Marquis P, Rummnas TA. Clinical Significance Consensus Meeting Group: the clinical significance of quality-of-life results: practical considerations for specific audiences. *Mayo Clin Proc* 2002;77:572-583.
4. Carlson ML, Tveiten OV, Driscoll CL et al. Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation and nontumour controls. *J Neurosurg* 2015;122:833-842.
5. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
6. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. *BMJ* 1993;306:1437-1440.
7. Turel MK, Thakar S, Rajshekhar V. Quality of life following surgery for large and giant vestibular schwannomas: a prospective study. *J Neurosurg* 2015;122:303-311.
8. Scheich M, Ginzkey C, Reuter E, Harnisch W, Ehrmann D, Hagen R. Quality of life after microsurgery for vestibular schwannoma via the middle cranial fossa approach. *Eur Arch Otorhinolaryngol* 2014;271:1909-1916.

9. Rameh C, Magnan J. Quality of life patients following stages III-IV vestibular schwannoma surgery using the retrosigmoid and translabyrinthine approaches. *Auris Nasus Larynx* 2010;37:546-552.
10. Cheng S, Naidoo Y, da Cruz M, Dexter M. Quality of life in postoperative vestibular schwannoma patients. *Laryngoscope* 2009;119:2252-2257.
11. Browne S, Distel E, Morton RP, Petrie KJ. Patients' quality of life, reported difficulties and benefits following surgery for acoustic neuroma. *J Otolaryngol Head Neck Surg* 2008;37:417-422.
12. Pollock BE, Driscoll CL, Foote RL et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. *Neurosurgery* 2006;59:77-85.
13. Godefroy WP, Hastan D, van der Mey AG. Translabyrinthine surgery for disabling vertigo in vestibular schwannoma patients. *Clin Otolaryngol* 2007;32:167-172.
14. Nicoucar K, Momjian S, Vader JP, de Tribolet N. Surgery for large vestibular schwannomas: how patients and surgeons perceive quality of life. *J Neurosurg* 2006;105:205-212.
15. Tufarelli D, Meli A, Alesii A et al. Quality of life after acoustic neuroma surgery. *Otol Neurotol* 2006;27:403-409.
16. Baumann I, Polligkeit J, Blumenstock G, Mauz P, Zalaman IM, Maassen MM. Quality of life after unilateral acoustic neuroma surgery via middle cranial fossa approach. *Acta Otolaryngol* 2005;125:585-591.
17. Betchen SA, Walsh J, Post KD. Self-assessed quality of life after acoustic neuroma surgery. *J Neurosurg* 2003;99:818-823.
18. Kelleher MO, Fernandes MF, Sim DW, O'Sullivan MG. Health-related quality of life in patients with skull base tumours. *Br J Neurosurg* 2002;16:16-20.

19. Martin HC, Sethi J, Lang D, Neil-Dwyer G, Lutman ME, Yardley L. Patient-assessed outcomes after excision of acoustic neuroma: post-operative symptoms and quality of life. *J Neurosurg* 2001;94:211-216.
20. Da Cruz MJ, Moffat DA, Hardy DG. Postoperative quality of life in vestibular schwannoma patients measured by the SF36 health questionnaire. *Laryngoscope* 2000;110:151-155.
21. Iyer AP, Gunn R, Sillars H. Quality of life after vestibular schwannoma surgery: does hearing preservation make a difference? *JLO* 2010;124:370-373.
22. Sandooram D, Hornigold R, Grunfeld B, Thomas N, Kitchen ND, Gleeson M. The effect of observation versus microsurgical excision on quality of life in unilateral vestibular schwannoma: A prospective study. *Skull Base* 2010;20:47-54.
23. Di Maio S, Akagami R. Prospective comparison of quality of life before and after observation, radiation or surgery for vestibular schwannomas. *J Neurosurg* 2009;111:855-862.
24. Nikolopoulos TP, Johnson I, O'Donoghue GM. Quality of life after acoustic neuroma surgery. *Laryngoscope* 1998;108:1382-1385.
25. Carlson ML, Tveiten OV, Driscoll CL et al. What drives quality of life in patients with sporadic vestibular schwannoma? *Laryngoscope* 2015;125:1697-1702.
26. Irving RM, Beynon GJ, Viani L, Hardy DG, Baguley DM, Moffat DA. The patient's perspective after vestibular schwannoma removal: quality of life and implications for management. *Am J Otol* 1995;16(3):331-337.
27. Sandooram D, Grunfeld EA, McKinney C, Gleeson MJ. Quality of life following microsurgery, radiosurgery and conservative management for unilateral vestibular schwannoma. *Clin Otolaryngol* 2004;29:621-627

28. Brooker JE, Fletcher JM, Dally MJ et al. Quality of life among acoustic neuroma patients managed by microsurgery, radiation or observation. *Otol Neurotol* 2010;31:977-984.
29. Myrseth E, Moller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen T, Lund-Johansen M. Vestibular schwannomas: clinical results and quality of life after microsurgery or gamma knife radiosurgery. *Neurosurgery* 2005;56:927-935.
30. Vogel JJ, Godefroy WP, van der Mey AG, le Cessie S, Kaptein AA. Illness perceptions, coping and quality of life in vestibular schwannoma patients at diagnosis. *Otol Neurotol* 2008;29:839-845.
31. Hio S, Kitahara T, Uno A, Imai T, Horii A, Inohara H. Psychological condition in patients with an acoustic tumour. *Acta Otolaryngol* 2013;133:42-46.
32. Tos T, Caye-Thomasen P, Stangerup SE, Tos M, Thomsen J. Patients' fears, expectations and satisfaction in relation to management of vestibular schwannoma: a comparison of surgery and observation. *Acta Otolaryngol* 2003;123:600-605.
33. Jorgensen B, Pedersen CB. Medical and socio-economic status of patients operated on for acoustic neuroma. In: Tos M, Thomsen J, eds. *Acoustic Neuroma*. Amsterdam, New York: Kugler, 1992:887-90.
34. Farace E, Marshall LF. Quality of life in acoustics. *J Neurosurg* 2003;99:807-809.
35. Magliulo G, Zardo F, Damico R, Varacalli S, Forino M. Acoustic neuroma: postoperative quality of life. *J Otolaryngol* 2000;29:344-347.
36. Pritchard C, Clapham L, David A, Lang DA, Neil-Dwyer G. Psycho-socio-economic outcomes in acoustic neuroma patients and their careers related to tumour size. *Clin Otolaryngol* 2004;29:324-330.

37. Broomfield SJ, O'Donoghue GM. Self-reported symptoms and patient experience: A British Acoustic Neuroma Association survey. *Br J Neurosurg* 2016;30(3):294-301.
38. Lassaletta L, Alfonso C, Del Rio L, Roda JM, Gavilan J. Impact of facial dysfunction on quality of life after vestibular schwannoma surgery. *Ann Otol Rhinol Laryngol* 2006;115:694-698.
39. Ryzenman JM, Pensak ML, Tew JM Jr. Patient perception of comorbid conditions after acoustic neuroma management: survey results from the Acoustic Neuroma Association. *Laryngoscope* 2004;114:814-820.
40. Neary WJ, Hiller VF, Flute T, Stephens SD, Ramsden RT, Evans DG. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. *Clin Otolaryngol* 2010;35:291-299.
41. Lloyd SK, Kasbekar AV, Baguley DM, Moffat DA. Audiovestibular factors influencing quality of life in patients with conservatively managed sporadic vestibular schwannoma. *Otol Neurotol* 2010;31:968-976.
42. Myrseth E, Moller P, Wentzel-Larsen T, Goplen F, Lund-Johansen M. Untreated vestibular schwannomas: vertigo is a powerful predictor for health-related quality of life. *Neurosurgery* 2006;59:67-76.
43. Inoue Y, Ogawa K, Kanzaki J. Quality of life of vestibular schwannoma patients after surgery. *Acta Otolaryngol* 2001;121:59-61.
44. Cross T, Sheard C, Garrud P, Nikolopoulos TP, O'Donoghue G. Impact of facial paralysis on patients with acoustic neuroma. *Laryngoscope* 2000;110:1539-1542.
45. Ryzenman JM, Pensak ML, Tew JM Jr. Facial paralysis and surgical rehabilitation: a quality of life analysis in a cohort of 1,595 patients after acoustic neuroma surgery. *Otol Neurotol* 2005;26:516-521.

46. Dutton JEM, Ramsden RT, Lye RH et al. Acoustic neuroma (schwannoma) surgery 1978 – 1990. *JLO* 1991;105:165-173.

47. Shaffer BT, Cohen MS, Bigelow DC, Ruckenstein MJ. Validation of a disease-specific quality-of-life instrument for acoustic neuroma: The Penn Acoustic Neuroma Quality-of-Life Scale. *Laryngoscope* 2010;120:1646-1654.

Legends for Figures

Figure 1. Graphical comparison of SF-36 scores in this study with UK normative data

Appendix 1. Post-operative survey (referred to in text as QOL-2)

In general, how has your *overall quality of life* changed, if at all, as a result of the operation?*

In general, how has your *overall health* changed, if at all, as a result of the operation?*

What was your occupation *before* the operation?*

What effect, if any, did your operation have on your ability to continue working?*

What effect, if any, did your operation have on your ability to drive a car?*

What effect, if any, did your operation have on your ability to continue with sports or hobbies?*

What effect, if any, has the operation had on your overall mood?*

Following the operation, did you notice any unusual or vivid dreams or nightmares?*

How did your actual experience of the operation and recovery compare to what you expected?*

Please tell us which of the following symptoms you had *before* and *after* the operation, and how much they affected your daily life (washing, dressing, going out, housework etc.)†

Loss of hearing

Tinnitus (ringing in the ears)

Loss of balance

Headache/ earache

Facial weakness


Eye problems (as a result of facial weakness)

Other (please specify)

* Subject asked to select from five point Likert scale with appropriate options depending on the question (see text)

† Subject asked to select from options: none; mild (noticed but not concerned); moderate (bothered but continue with daily life); severe (a frequent or constant problem. Affects daily life or sleep)

Broomfield et al Figure 1



Broomfield et al Tables

Table 1. SF-36 scores for study respondents (n= 334) and comparison with UK normative data.

	This study (Mean, SD)	This study (Median, IQR)	UK Norms (Mean, SD)	Difference
PF	72.86 (29.06)	85 (55-95)	87.8	-14.9
RP	72.13 (31.43)	81 (50-100)	85.8	-13.7
BP	70.75 (28.59)	74 (51-100)	81.5	-10.8
GH	62.25 (25.50)	67 (42-82)	72.7	-10.5
VT	52.81 (11.11)	50 (50-56)	61.4	-8.6
SF	50.14 (9.90)	50 (50-50)	88.1	-38.0
RE	80.50 (28.74)	100 (75-100)	83.1	-2.6
MH	63.49 (10.44)	65 (60-70)	70.4	-6.9
TPCS	47.68 (12.65)	50.4 (40.3 – 58.2)	-	-
TMCS	42.38 (6.61)	42.4 (39.0 – 45.8)	-	-

PF - physical functioning, RP - role limitations due to physical health, BP - bodily pain, GH - general health, VT – vitality, SF - social functioning, RE - role limitations due to emotional health, MH - general mental health, TPCS - total physical component score, TMCS - total mental component score.

Table 2. Distribution of tumour sizes (n=334).

Tumour Size	n= (%)
Intracanalicular	26 (7.8)
<1cm	29 (8.7)
1cm<2cm	119 (35.6)
2cm<3cm	75 (22.5)
3cm<4cm	45 (13.5)
>=4cm	23 (6.9)
Data missing	17 (5.1)

Table 3. Estimated effects of tumour sizes on the TPCS and TMCS SF-36 domains using linear regression analysis adjusted for age.

SF-36 Domain	Tumour Size							
	1cm < 2cm		2cm <3cm		3cm <4cm		>= 4cm	
	<i>Effect (95% CI)</i>	<i>P value</i>	<i>Effect (95% CI)</i>	<i>P value</i>	<i>Effect (95% CI)</i>	<i>P value</i>	<i>Effect (95% CI)</i>	<i>P value</i>
TPCS	0.7 (-3.3,4.7)	0.743	-0.4 (-4.8,3.9)	0.840	-0.6 (-5.5,4.3)	0.811	1.5 (-4.8,7.7)	0.644
TMCS	-1.8 (-3.8,0.3)	0.096	-1.2 (-3.5,1.1)	0.295	-2.5 (-5.0,0.1)	0.056	-3.4 (-6.6,-0.2)	0.037

TPCS - total physical component score, TMCS - total mental component score.

Table 4. Relationship between age at time of surgery and SF-36 scores.

	PF	RP	BP	GH	VT	SF	RE	MH	TPCS	TMCS
Correlation	-0.29	-0.2	-0.16	-0.06	0.16	0.04	0.48	0.13	-0.26	0.26
P Value	<0.01	<0.01	<0.01	0.25	<0.01	0.53	0.48	0.02	<0.01	<0.01

PF - physical functioning, RP - role limitations due to physical health, BP - bodily pain, GH - general health, VT – vitality, SF - social functioning, RE - role limitations due to emotional health, MH - general mental health, TPCS - total physical component score, TMCS - total mental component score.

Table 5. Self-report of effect of surgery on overall quality of life and overall health

(n, %)	A lot better	A little better	Unchanged	A little worse	A lot worse
Overall QOL (n=369)	62 (16.8)	26 (7.0)	100 (27.1)	138 (37.4)	43 (11.7)
Overall health (n=367)	48 (13.1)	27 (7.4)	140 (38.1)	112 (30.5)	40 (10.9)

QOL – Quality of Life

Table 6. Self-grading of pre- and post-operative symptoms with regards to their effect on daily activities. Boxes indicate number of patients.

		Post-operative													
Pre-operative	Change in Hearing		None	Mild	Mod.	Severe	NA	Total	Tinnitus†	None	Mild	Mod.	Severe	NA	Total
		None	5	3	13	16	1	38		98	15	18	10	6	147
		Mild	3	7	55	30	3	98		10	43	21	8	5	87
		Mod.	1	6	96	74	2	179		9	16	44	9	2	80
		Sever	3	0	10	29	1	43		3	3	7	29	0	42
		NA	1	1	2	5	2	11		3	2	1	1	6	13
		Total	13	17	176	154	9	369		123	79	91	57	19	369
	Loss of balance	None	39	45	31	13	2	130	Headache/earache	142	19	19	5	11	196
		Mild	5	23	27	12	3	70		23	28	4	4	1	60
		Mod.	9	28	56	12	1	106		21	11	17	13	2	64
		Sever	5	12	8	22	1	48		7	11	8	5	1	32
		NA	1	4	3	2	5	15		5	0	0	1	11	17
		Total	59	112	125	61	12	369		198	69	48	28	26	369
	Facial weakness	None	123	52	57	29	5	266	Eye problems†	139	64	53	35	7	298
		Mild	10	27	9	3	1	50		4	14	3	2	1	24
		Mod.	4	6	12	3	1	26		3	5	13	2	2	25
		Sever	0	3	2	2	1	8		0	0	1	5	1	7
		NA	4	5	1	1	8	19		3	3	0	2	7	15
Total		141	93	81	38	16	369	149		86	70	46	18	369	

NA – Not answered

† Tinnitus was further defined as ‘ringing in the ears’. Eye problems were defined as those specifically related to facial weakness.

Table 7. Comparison of published SF-36 scores with present study in patients following surgical management of acoustic neuroma

	This Study	Carlson <i>et al</i> ⁴	Turel <i>et al</i> ⁷	Scheich <i>et al</i> ⁸	Rameh <i>et al</i> ⁹	Cheng <i>et al</i> ¹⁰	Browne <i>et al</i> ¹¹	Pollock <i>et al</i> ¹²	Godefroy <i>et al</i> ¹³	Nicoucar <i>et al</i> ¹⁴	Tufarelli <i>et al</i> ¹⁵	Bauman <i>n et al</i> ¹⁶	Betchen <i>et al</i> ¹⁷	Kelleher <i>et al</i> ¹⁸	Martin <i>et al</i> ¹⁹	
Year	2016	2015	2015	2014	2010	2009	2008	2007	2007	2006	2006	2005	2003	2002	2001	
QOL tool	SF-36	SF-36	SF-36	SF-36	SF-36	SF-36	SF-36	HSQ	SF-36	SF-36	SF-36	SF-36	SF-36	SF-36	SF-36	
Region of Study	UK	US/ Norway	India	Germany	France	Australia	New Zealand	USA	Holland	Switzerland	Italy	Germany	USA	UK	UK	
Surgery route	TL	All	SO	MF	TL*, RS	TL, RS	Most TL	All	TL	RS	All	MF	TL, SO	NS	TL	
N=	334	144	100	86	59	98	85	36		72	386	42	101	19	76	
Age (years)	51.9	Mean 58 (SD NS)	Mean 44.2 (SD 11.5)	Mean 53.5 (11.7)	Mean 55.2 (SD 11.4)	Mean 55 (SD NS)	Mean 59 (SD 11.0)	Mean 48.2 (SD NS)	Mean 55.9 (41-69)	Mean 50.8 (SD NS)	Mean 49.4 (SD 12.1)	Median 57	Mean 52 (23-79)	Median 44.1	Mean 52 (16-74)	
Tumour size (cm)	Median 1.5 (IQR1-2.5)	<= 3 (Mean NS)	Mean 4.2 (3 – 6.6)	Stage I and II	>2 Stage III/ IV	Mean 2.2 (SD NS)		Mean 1.4 (excl. IC)	IC Patients had severe vertigo	Stage III/ IV	14% IC 40% 0.1-1.5 46%>1.5	27% <1 73% >1		Average NS	Mean 2.5 (SD NS) (0.5-5.5)	
Follow-up (months/years)	Median 8yrs (IQR 7-10)	Mean 7.7 yrs (SD NS)	NS	>6mo	Mean 5.9yrs (SD 2.0)	>6 mo	6.9yrs (SD 5.7)	>12mo	12	Mean 7.6yrs (6-228mo)	Mean 4yrs (SD 2.4)	Median 3.1yrs (range 1-5.3)	>6mo	36.8mo (14-176mo)	Mean 18mo	
SF-36 Subscale	Mean (SD)	Median (IQR)	Mean (SD NS)	Mean (SD)	Mean (SD NS)	Mean (SD)	Mean (SD)	Mean (SD NS)	Mean (SD)		Mean (SD NS)	Mean (SD)	Median (IQR)	Mean (SD NS)	Mean (SD NS)	Median (IQR)
PF	72.86 (29.06)	85 (55-95)	-	69.6 (24.6)	72.7	78.2 (24.8)	76.2 (28.1)	78.8	87.1 (16.8)	77.1 (12.8)	-	77.8 (27.7)	82.5 (65-91.2)	82.5	77.6	73 (45-95)
RP	72.13 (31.43)	81 (50-100)	-	48.5 (38.7)	62.3	49.2 (42.6)	63.8 (43.7)	67.8	81.2 (30.4)	70.6 (20.2)	56.6	66.7 (40.6)	87.5 (0-100)	71.7	57.9	25 (0-100)
BP	70.75 (28.59)	74 (51-100)	-	68.3 (23.3)	75.1	87.3 (25.2)	74.3 (26.5)	77.9	76.2 (24.1)	69.7 (22.7)	72.5	67.9 (25.1)	74 (48.7 - 100)	60.5	77.2	84 (61-100)
GH	62.25 (25.50)	67 (42-82)	-	63 (21.6)	57.1	58.9 (21.0)	67.1 (25.6)	73.8	70.9 (20.3)	70.6 (13.7)	68.2	60.6 (25.5)	61 (38.7 – 77)	71.3	68.6	77 (41-87)
VT	52.81 (11.11)	50 (50-56)	-	61 (18.9)	50.2	51.1 (19.0)	61.4 (22.9)	65.6	60.8 (19.0)	62.1 (17.0)	55.1	55.1 (23.9)	55 (33.7-80)	63.8	60.3	48 (35-65)
SF	50.14 (9.90)	50 (50-50)	-	70.6 (24.7)	71.4	76.7 (28.6)	78.4 (27.9)	86.6	85.1 (22.2)	79.4 (17.1)	65.8	73.2 (25.4)	81.2 (62.5 - 100)	79.8	68.8	75 (38-100)
RE	80.50 (28.74)	100 (75-100)	-	54.8 (43)	62.8	59.3 (49.5)	77.6 (35.1)	73.9	92.2 (22.6)	72.5 (29.4)	67.1	67.7 (41.4)	100 (0-100)	73.9	75.4	100 (33-100)
MH	63.49	65	-	68.7 (19.6)	64.7	55.9 (23.7)	75.5 (19.3)	63.2	76.1 (15.9)	72.9 (19.6)	66.8	61.7 (26.9)	74 (56-80)	71.5	67.2	72 (56-88)

	(10.44)	(60-70)														
TPCS	47.68 (12.65)	50.4 (40.3 – 58.2)	49	-	-	-	-	-	49.2 (8.2)	-	-	-	-	-	-	-
TMCS	42.38 (6.61)	42.4 (39.0 – 45.8)	51	-	-	-	-	-	51.6 (8.1)	-	-	-	-	-	-	-

QOL – Quality of Life, HSQ – Health Status Questionnaire (modified SF-36)

TL – Translabyrinthine, RS – Retrosigmoid, MF – Middle cranial fossa, SO – Suboccipital, IC - Intracanalicular

SD – Standard deviation, IQR – Interquartile range

NS – Not specified

* - SF-36 data shown only for patients operated with the translabyrinthine approach, for more direct comparison